Vimarsana
Biggest News Aggregation in the World

Page 24 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022 - Vimarsana News

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

/PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced...

NovalGen announces compelling data from the Phase 1/2 Study - Vimarsana News

NovalGen announces compelling data from the Phase 1/2 Study

- First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates...

Merus N.V.: Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Vimarsana News

Merus N.V.: Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be well-tolerated - Oral presentation with additional

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference - Vimarsana News

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference

/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer,...

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results - Vimarsana News

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results

-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory m...